How BeOne Has Grown Alongside Our Pipeline
One employee joined Germany’s team as its seventh hire in 2021. Hear her describe how the team has expanded since then.
“When we started, we were a one-product company. Now it’s totally different.”
BeOne’s Journey: From One Product to an Expanding Pipeline
BeOne Medicines is now advancing one of the industry’s most prolific and promising pipelines. It all started with a single drug, when BRUKINSA® (zanubrutinib) received the FDA’s approval in 2019 and became a foundational hematological medicine. Later TEVIMBRA® (tislelizumab-jsgr) established our presence in solid tumor therapeutics.
Our pipeline has continued expanding, and our company has mirrored that growth, reaching about 12,000 employees in 2025. See our pipeline to learn more about transformational treatments we are developing.
